

## **CURRICULUM VITAE**

**Name:** Petri Bono  
**Date of birth:** March 20, 1970



### **Present position:**

2016- Chief Medical Officer, Helsinki University Hospital (HUH), Helsinki, Finland  
2006- Adjunct Professor (cancer biology), University of Helsinki, Finland

### **Education and Academic Degrees:**

2015-2016 Executive education, Harvard Business School (Managing health care delivery)  
2006 Specialist in Medical Oncology, University of Helsinki  
2006 Adjunct professor, University of Helsinki  
1999-2000 Post-doctoral researcher (Hynes Lab), MIT Centre for Cancer Research, Boston, USA  
1996 M.D., University of Turku; 1998 Ph.D., University of Turku

### **Professional experience:**

2013-2016 Director and Physician-in-Chief, Comprehensive Cancer Center, HUH  
2010-2013 Physician-in-Chief, Department of Medicine and Cancer Clinic Group, HUH  
2008-2009 Head of Chemotherapy, Department of Oncology, HUH  
2000-2007 Resident/specialist in oncology, HUH

### **Board Affiliations:**

Orion Research Foundation 2012- (vice chairman)  
Instru foundation 2014- (board member)  
Clinical Research Institute HUH Ltd 2014- (board member)  
HUS Kiinteistöt Ltd (board member) 2017-  
TILT therapeutics (member of Scientific Advisory Board) 2014-  
ESMO (European Society of Clinical Oncology) genitourinary cancer Scientific Advisory Board (board member) 2016-

### **Stock Ownership:**

TILT Biotherapeutics

### **Clinical research experience:**

Member of trial steering group in 8 international studies  
Investigator in >45 phase I-III studies 2001-2018  
National principal investigator in 16 phase I-III studies (including 6 first-in-man phase 1)  
Certified GCP-test by the Pharmaceutical Information Centre Ltd. 2008, 2012 and 2017

**Publications:** 84 peer –reviewed papers (listed in PubMed); Additional papers in Finnish, 9; Chapters in books:3; Multiple abstracts in international oncology meetings

**Mean Impact Factor of Publications:** 9.863

**Supervised PhD thesis: 2; PhDs under supervision:2; Reviewer of dissertation/docentship:3; Opponent: 2 times**

### **Memberships in societies and organisations**

American Society of Clinical Oncology 2010-

European Society of Clinical Oncology 2011-

Finnish Medical Association 1996-

Finnish Medical Society Duodecim 1997-

Finnish Society of clinical Oncology 2001-

### **Examples of publications:**

Fizazi K, Massard C, **Bono P** et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label, phase 1 dose-escalation and randomised phase 2 dose expansion trial. **Lancet Oncology** 2014;15:975-85.

Sharma P, Callahan MK, **Bono P**, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial. **Lancet Oncology** 2016;17:1590-98.

Antonia SJ, López-Martin JA, Bendell J,...**Bono P**, Atmaca A, Sharma P, Harbison C, Lin CS, Christensen O and Calvo E. Nivolumab Alone or in Combination with Ipilimumab in Recurrent Small-Cell Lung Cancer. **Lancet Oncology** 2016;17:883-95.

Joensuu H, Kellokumpu-Lehtinen P-L, **Bono P**, et al. Trastuzumab in Combination with Vinorelbine or Docetaxel as Adjuvant Treatment of Breast Cancer with *erbB-2* Gene Amplification. **New England Journal of Medicine** 2006, 354: 809-20.

Motzer RJ, Escudier B, McDermott DF,...**Bono P**, Wagstaff J, Gaurer TC, Ueda T, Tomita Y, Barros Schutz FA, Kollmannsberger CK, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM and Sharma P. Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma. **New England Journal Of Medicine** 2015;373:1803-13.

Rautiola J, Donskov F, Peltola K, Joensuu H and **Bono P**. Sunitinib-induced hypertension, neutropenia and thrombocytopenia as predictors of good prognosis in metastatic renal cell carcinoma patients. **BJUI** 2016;117:110-7.

**Bono P**, Oudard S, Bodrogi I et al. Outcomes in patients with metastatic renal cell carcinoma who develop everolimus-related hyperglycemia and hypercholesterolemia: Subgroup analyses of RECORD-1 and REACT trials. **Clinical Genitourinary Cancer** 2016;14:406-414.

Penttilä P, Rautiola J, Peltola K, Poussa T and **Bono P**. Angiotensin-inhibitors as treatment of sunitinib/pazopanib induced hypertension in metastatic renal cell carcinoma. **Clinical Genitourinary Cancer** 2017;15:384-90.